New possibilities of targeted therapy for advanced hormone receptor-positive breast cancer
Journal Title: OncoReview - Year 2012, Vol 2, Issue 2
Abstract
Molecular studies have shown that breast cancer is a heterogeneous disease with different biological features and different prognosis. From clinical point of view breast cancer patients could be divided into three types with diverse sensitivity to therapy. In one of these groups hormone receptor positive breast cancers are sensitive to endocrine treatment. This therapy is the primary treatment of breast cancer patients and is also the oldest method of systemic treatment. Due to high efficacy and good toxicity profile is widely used. Unfortunately not all patients with hormone receptor-positive breast cancer have the same benefit. Many of them progress despite prior good response to such treatment. There are many reasons for that. One of them is the existing cross-talk between estrogen receptors and the other signaling pathways. Intracellular phosphoinositide 3-kinase pathway (PI3K/Akt/mTOR) is the major site of transmission and cross-talks associated with the activity of human epidermal growth factor receptors and other receptor tyrosine kinases. The PI3K pathway is frequently aberrantly activated in breast cancers. Everolimus is a drug that inhibits the proliferation signals by inhibiting mTOR kinase activity. This protein plays a key role in the regulation of cell division and blood vessel growth. The combination of endocrine therapy with inhibition of PI3K and mTOR improved treatment results, as it was shown in randomized phase III study. These results may set a new standard of care for women with advanced hormone receptorpositive breast cancer.
Authors and Affiliations
Tadeusz Pieńkowski
Keywords
Related Articles
- EP ID EP53146
- DOI -
- Views 251
- Downloads 0
Stanowisko w sprawie stosowania niepegylowanej liposomalnej doksorubicyjny u chorych na chłonniaki ze współistniejącymi chorobami sercowo-naczyniowymi
Early molecular response as a criterion of optimal response to chronic myeloid leukemia treatment with tyrosine kinase inhibitors
Maximal reduction of leukemic BCR/ABL-positive cells and achievement of persistent deep molecular response with the chance for sustained treatment-free survival in possibly all patients is a current goal of chronic myelo...
Acromegaly: the effect of somatostatin analogues on tumour volume shrinkage
Acromegaly is a rare disease, caused by growth hormone (GH) hypersecretion and secondarily elevated insulin-like growth hormone 1 (IGF-1) level. Nearly all patients with acromegaly suffer from somatotroph pituitary adeno...
The cardiac safety during treatment with sunitinib and sorafenib, multikinase angiogenesis inhibitors
Cardiotoxicity of multikinase angiogenesis inhibitors, sunitinib and sorafenib, is most often myocardial systolic dysfunction or arterial and venous thromboembolic events. Essential risk factor seems to be iatrogenic art...
A role of JAK in the pathogenesis of Philadelphia negative myeloproliferative neoplasms. Target therapy possibilities
In recent years a significant progress has been made in understanding of the pathogenesis of myeloproliferative neoplasms, especially the one with mutation in JAK2 gene. In 2005 several study groups confirmed the presenc...